Winrevair (sotatercept-csrk) / BMS, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 16 Diseases   13 Trials   13 Trials   579 News 


«1234567»
  • ||||||||||  sotatercept (MK-7962) / BMS, Merck (MSD)
    We need SOTATERCEPT (Twitter) -  May 23, 2023   
  • ||||||||||  HS135 / 35Pharma
    HS135, a Novel Activin and GDF Trap, Is Efficacious in Models of Pulmonary Hypertension (PH) and Heart Failure (HF) (Walter E. Washington Convention Center, Area B, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_5746;    
    The best-in-class target engagement profile of HS135 translates into increased and differentiated efficacy improving the PH and HF phenotype in preclinical models. Collectively, these data support the development of HS135 as a novel agent in cardiometabolic and cardiopulmonary diseases including PAH and PH-associated with left heart disease.
  • ||||||||||  sotatercept (MK-7962) / BMS, Merck (MSD)
    P3 data, Journal:  Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. (Pubmed Central) -  Mar 7, 2023   
    P3
    In patients with pulmonary arterial hypertension who were receiving stable background therapy, sotatercept resulted in a greater improvement in exercise capacity (as assessed by the 6-minute walk test) than placebo. (Funded by Acceleron Pharma, a subsidiary of MSD; STELLAR ClinicalTrials.gov number, NCT04576988.).
  • ||||||||||  Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
    Trial primary completion date:  CADENCE: A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16) (clinicaltrials.gov) -  Oct 31, 2022   
    P2,  N=150, Recruiting, 
    Other molecules affecting anaemia, such as sotatercept, have also been confirmed to be effective in phase 1 and 2 clinical trials and are awaiting results from larger randomised trials. Trial primary completion date: Aug 2023 --> Jan 2024
  • ||||||||||  sotatercept (MK-7962) / BMS, Merck (MSD), Reblozyl (luspatercept-aamt) / BMS, Merck (MSD)
    Journal:  Detection of activin receptor type IIA and IIB-Fc fusion proteins by automated capillary immunoassay. (Pubmed Central) -  Oct 7, 2022   
    The recent approval of Luspatercept for the treatment of anemia associated to transfusion-dependent MDS and Beta-thalassemia in afflicted patients means that it can now pose a real threat of being abuse in sport for its ability to stimulate erythropoiesis...The option to use different antibodies allows the possibility to use this method as an initial testing procedure as well as a confirmation procedure. Finally, results coming from an administration study confirm that the method is suitable for routine analysis.
  • ||||||||||  Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
    Trial completion date, Trial primary completion date:  A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR) (clinicaltrials.gov) -  Sep 23, 2022   
    P3,  N=324, Active, not recruiting, 
    Finally, results coming from an administration study confirm that the method is suitable for routine analysis. Trial completion date: Apr 2023 --> Nov 2022 | Trial primary completion date: Dec 2022 --> Aug 2022
  • ||||||||||  Journal:  Evolving nonvasodilator treatment options for pulmonary arterial hypertension. (Pubmed Central) -  Aug 11, 2022   
    Pharmacologic approaches for the treatment of PAH include altering of transforming growth factor β/BMPR2 signaling, proliferation via growth factors, immune response, oxidative stress, estrogen signaling, metabolism, and neurohormonal modulation. Other treatment modalities including pulmonary artery nerve denervation, stem cell therapy, and inter-atrial shunt formation are also being explored.
  • ||||||||||  PH.CVS.58. Cardiogenic Shock Plus: Management of Complex Cardiac Pathologies in the CICU (103C) -  Jul 17, 2022 - Abstract #AHA2022AHA_1430;    
    DESCRIPTION This education session was planned by the Committee on Scientific Sessions Program. Expert approaches to management of overlapping cardiogenic shock syndromes including distributive, valvular, and arrhythmogenic aetiologies and role for temporary MCS strategies
  • ||||||||||  Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
    Trial completion, Trial completion date, Trial primary completion date:  Sotatercept in Treating Patients With Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia (clinicaltrials.gov) -  Jun 22, 2022   
    P2,  N=63, Completed, 
    Expert approaches to management of overlapping cardiogenic shock syndromes including distributive, valvular, and arrhythmogenic aetiologies and role for temporary MCS strategies Active, not recruiting --> Completed | Trial completion date: Feb 2022 --> May 2022 | Trial primary completion date: Feb 2022 --> May 2022
  • ||||||||||  sotatercept (MK-7962) / BMS, Merck (MSD)
    Effect of sotatercept on multicomponent improvement in the PULSAR study (8L) -  Jun 22, 2022 - Abstract #ERS2022ERS_2216;    
    A greater proportion of sotatercept-treated pts with a range of baseline risk-scores achieved MCI vs placebo. Pts improved upon switch from placebo and continued to improve with longer-term treatment.
  • ||||||||||  sotatercept (MK-7962) / BMS, Merck (MSD)
    Journal:  Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension. (Pubmed Central) -  May 21, 2022   
    Three high-affinity ligands of ActRIIA-Fc each induced macrophage activation in vitro, and their combined immunoneutralization in PAH rats produced cardiopulmonary benefits comparable to those elicited by ActRIIA-Fc. Our results in complementary experimental and genetic models of PAH reveal therapeutic anti-inflammatory activities of ActRIIA-Fc that, together with its known anti-proliferative effects on vascular cell types, could underlie clinical activity of sotatercept as either monotherapy or add-on to current PAH therapies.
  • ||||||||||  rodatristat ethyl (RVT-1201) / Sumitomo Dainippon, sotatercept (ACE-011) / BMS, Merck (MSD)
    Review, Journal:  "NOVEL MECHANISMS TARGETED BY DRUG TRIALS IN PULMONARY ARTERIAL HYPERTENSION". (Pubmed Central) -  Apr 13, 2022   
    In this review, we will discuss the preclinical studies that led to prioritization of these mechanisms and will discuss recently completed and ongoing phase 2/3 trials using novel interventions such as sotatercept, anastrozole, rodatristat ethyl, tyrosine kinase inhibitors, and endothelial progenitor cells among others. We anticipate that the next generation of compounds will build upon the success of the current standard of care and improve clinical outcomes and quality of life of patients afflicted with PAH.
  • ||||||||||  Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
    Trial completion, Trial completion date:  SPECTRA: A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (clinicaltrials.gov) -  Mar 25, 2022   
    P2a,  N=21, Completed, 
    We anticipate that the next generation of compounds will build upon the success of the current standard of care and improve clinical outcomes and quality of life of patients afflicted with PAH. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Mar 2022